Project Grant R41DK143902
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $347K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
- This Project Grant award of $806,192 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to delineate how a deficiency in the ATP-binding cassette protein MRP9 causes injury to cholangiocytes, the cells that line the bile ducts, in chronic cholestatic liver diseases. The research is being conducted by the Children's Hospital Medical...
- This Project Grant award of $215,700 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) is supporting research at Baylor College of Medicine to investigate the use of the antibiotic rifaximin to reduce bacterial-derived inflammation and subsequent liver fibrosis in neonatal cholestasis, a leading cause of pediatric liver transplants. The research aims to explore whether suppressing gut...
- This $324,984 Project Grant was awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Syntis Bio Inc., is developing an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. The project involves optimizing a formulation that combines a protease-stable enzyme (methionine-gamma-lyase) with a...
- This federal Project Grant award of $305,786 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Cypress Biopharma, Inc. The grant supports research to develop a novel non-immunosuppressive therapy for childhood nephrotic syndrome (NS). The project aims to leverage the highly active metabolite of pioglitazone as a scaffold to design a drug that can...
- This federal Project Grant award of $3,010,432 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to develop mitoprotective therapies for the treatment of acute kidney injury (AKI). The key objectives of this research are to characterize a novel mitochondrial protein target, phospholipid scramblase 3 (PLSCR3), and evaluate pharmacological activators...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $175,964 Project Grant to Hepatx Corporation in Palo Alto, CA on May 13, 2025. The grant aims to develop a proteomic assay, or blood test, to monitor the success of cell transplantation therapies, such as hepatocyte (liver cell) transplantation, for treating chronic diseases. This novel assay would enable the...
- This Project Grant award of $349,325 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The goal of the award is to develop an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD) by targeting the arginine-polyamine pathway. The awardee, Regennova, Inc., a small disadvantaged business located in North...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,022,055.00 to IVMT, LLC to advance the clinical utility of a targeted image contrast agent for detecting biliary intra-epithelial neoplasia. The project aims to conduct a Phase 2 multi-center study of a near-infrared fluorescently-labeled peptide heterodimer that binds with high...